Protara Therapeutics (TARA) Stock Overview
A clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
TARA Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Protara Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.65 |
| 52 Week High | US$7.82 |
| 52 Week Low | US$2.77 |
| Beta | 1.39 |
| 1 Month Change | 16.87% |
| 3 Month Change | 55.01% |
| 1 Year Change | 50.79% |
| 3 Year Change | 101.52% |
| 5 Year Change | -66.70% |
| Change since IPO | -77.83% |
Recent News & Updates
Recent updates
Protara Therapeutics: End Of 2025 Proving Eventful Indeed
Dec 04We Think Protara Therapeutics (NASDAQ:TARA) Can Afford To Drive Business Growth
Jul 10
Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results
Mar 28We're Hopeful That Protara Therapeutics (NASDAQ:TARA) Will Use Its Cash Wisely
Mar 07Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst
Dec 10Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation
Nov 22Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth?
Aug 08Protara: A Bombed Out Biotech With A Very Positive Skew
Feb 22Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation
Dec 16We Think Protara Therapeutics (NASDAQ:TARA) Can Afford To Drive Business Growth
Apr 22The Prognosis For Protara Therapeutics
Oct 13Here's Why We're Not Too Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation
Sep 12Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?
Mar 21Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Deliver On Growth Plans?
Dec 06Shareholder Returns
| TARA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.1% | 3.8% | -0.1% |
| 1Y | 50.8% | 29.5% | 13.8% |
Return vs Industry: TARA exceeded the US Biotechs industry which returned 22.1% over the past year.
Return vs Market: TARA exceeded the US Market which returned 10.3% over the past year.
Price Volatility
| TARA volatility | |
|---|---|
| TARA Average Weekly Movement | 13.8% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TARA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TARA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 31 | Jesse Shefferman | www.protaratx.com |
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids.
Protara Therapeutics, Inc. Fundamentals Summary
| TARA fundamental statistics | |
|---|---|
| Market cap | US$348.32m |
| Earnings (TTM) | -US$52.90m |
| Revenue (TTM) | n/a |
Is TARA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TARA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$52.90m |
| Earnings | -US$52.90m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.99 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TARA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/06 13:45 |
| End of Day Share Price | 2026/02/06 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Protara Therapeutics, Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Li Wang Watsek | Cantor Fitzgerald & Co. |
| Andres Maldonado | H.C. Wainwright & Co. |
| Andrew Fein | H.C. Wainwright & Co. |